Programme-level compliance for FDA, EMA, MHRA, PMDA, CDSCO.
Programme design, gap assessment and remediation across regulated processes — from CMC through post-market.
Regulatory compliance in life sciences means meeting the obligations of the authorities governing your products and processes — FDA, EMA, MHRA, PMDA, CDSCO — across manufacturing, clinical and post-market activity. It is a lifecycle state rather than a project outcome, and it decays through the obligations that have no project attached: periodic review, access review, supplier reassessment.
Outcomes you can expect
- Compliance gap report
- Prioritised remediation
- KPI-driven programme
Regulatory Compliance is delivered by our regulatory services practice. Where it saves time, the team uses our products: GxP Copilot for validation lifecycle work and TraceDraft for clinical documentation.
Explore related capabilities: Regulatory Intelligence, Regulatory Information Management (RIM), eQMS Implementation & Validation, Pharmacovigilance.
Programme-Level Regulatory Compliance: Beyond Individual System Fixes
Regulatory compliance in pharmaceutical, biotech, and medical device organisations is not a series of independent system audits — it is a programme-level discipline that spans the organisation's regulated processes from early development through post-market lifecycle. A company that passes each individual system audit but lacks a coherent compliance programme will eventually face a systematic finding: a pattern of data integrity issues that traces back to the same process design weakness across multiple systems, or a CAPA backlog that reveals a compliance culture gap rather than an operational problem.
Cybroscape's regulatory compliance consulting practice works at the programme level. We assess the compliance posture across the regulated process estate — from computerised systems through quality management processes, from CMC documentation through post-market surveillance — and develop an integrated compliance programme that addresses gaps systematically rather than reactively. The deliverable is not a report of findings; it is a functioning compliance programme with defined KPIs, a realistic remediation timeline, and the accountability structure to sustain it.
Multi-Authority Compliance: FDA, EMA, MHRA, PMDA, CDSCO
Life sciences organisations with global product portfolios face simultaneous compliance obligations across multiple regulatory jurisdictions. While FDA, EMA, MHRA, PMDA, and CDSCO all operate within the ICH framework, they differ in implementation emphasis, inspection approach, and the specific requirements they prioritise. An organisation that is well-prepared for FDA CDER inspection may have gaps against PMDA's expectations for Japanese market filings, or against MHRA's emphasis on data integrity in GMP systems.
Our multi-authority compliance services map the organisation's current compliance posture against each relevant regulatory framework, identify jurisdiction-specific gaps, and develop a prioritised remediation plan that addresses the highest-risk gaps across all authorities. For organisations planning regulatory submissions in new markets, we provide a market-entry compliance assessment that identifies the specific requirements of the target jurisdiction and the gap from the organisation's current state.
Sources
Primary documents referred to on this page, from their official publishers.
See it on your own system.
Bring a URS or a system. We show you the validation package it produces.
- We reply within one business day
- We run your URS live on the call
- You get a clear plan and scope